Publications by authors named "Mohammed Emadeldeen"

3 Publications

  • Page 1 of 1

Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.

Eur J Gastroenterol Hepatol 2021 Sep 21. Epub 2021 Sep 21.

Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo Tropical medicine, Faculty of Medicine, Alexandria University, Alexandria Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University Department of Internal Medicine, Al-Azhar University Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo Department of community medicine, Faculty of Medicine, Suez Canal University Hepatogastroenterology Department, National Hepatology & Tropical Medicine Research Institute, Cairo Gastroenterology Department, Damietta Cardiology and Gastroenterology Center, Damietta Hepatology and Gastroenterology Department, AGOZA Police Hospital, Cairo Epidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Menoufia, Egypt Hepatology and gastroenterology department, national liver institute.Menoufia University, Egypt.

Background: Hepatitis C virus (HCV)-related decompensated cirrhosis is a severe life-threatening illness. The safety of direct-acting antivirals (DAAs) has opened a gate of hope for that subgroup of patients who were previously contraindicated for interferon therapy.

Objective: We aimed at the investigation of the safety and efficacy of different DAAs regimens in the treatment of HCV-related decompensated cirrhosis patients, to determine sustained virological response (SVR)12 rates and to analyze the factors associated with response.

Methods: A retrospective, single-center study including HCV-related decompensated cirrhosis patients who received DAAs. Demographic, laboratory and clinical data were analyzed. The SVR12 rate was the primary outcome measure. Secondary outcomes included the predictors of response, changes in the baseline model for end-stage liver disease and child-turcotte-pugh (CTP) scores, and fibroindices (APRI and fibrosis-4 index) at 12 weeks after treatment.

Results: In total, 145 eligible patients (141 with CTP class B and 4 with class C) were enrolled in this study. SVR12 was achieved by 88.06% (118/134) of efficacy population on different DAAs regimens, Treatment was discontinued in 11 patients because of severe side effects without any deaths. Younger age showed a significant positive association with SVR12.

Conclusions: DAAs can be used for the treatment of HCV-related decompensated liver disease, with acceptable SVR12 rates and safety profiles.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000002287DOI Listing
September 2021

High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience.

Arch Virol 2020 Jul 30;165(7):1633-1639. Epub 2020 Apr 30.

Tropical Medicine Department, Tanta University, Tanta, Egypt.

The aim of this work was assessment of the efficacy and tolerability of two different regimens for retreatment of hepatitis C virus (HCV) patients who failed to respond to SOF/DCV-based therapy. This prospective study included 104 HCV patients who failed to respond to SOF/DCV-based therapy. Patients were randomly allocated to two groups. Efficacy and tolerability were assessed. The 12-week sustained virological response (SVR12) rates were 96% and 94.4% in groups B and A, respectively, with no significant difference (p = 1.000). Most adverse events reported were mild to moderate, with no deaths during the study. Multi-target direct-acting antiviral (DAA) combinations are efficient for retreatment of HCV patients after failure of SOF/DCV-based therapy in real-world management.ClinicalTrials.gov identifier: NCT02992457.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00705-020-04639-xDOI Listing
July 2020

The effects of nickel on the reproductive ability of three different marine copepods.

Ecotoxicology 2010 Jun 25;19(5):911-6. Epub 2010 Feb 25.

College of Oceanography and Environmental Science, State Key Laboratory of Marine Environmental Science, Xiamen University, 361005, Xiamen, People's Republic of China.

Lethal and sublethal toxicity of Nickel (Ni) to three marine copepods Tigriopus japonicus, Apocyclops borneoensis and Acartia pacifica was investigated. The 48-h LC50 values were 17.70, 13.05 and 2.36 mg l(-1) Ni, respectively. A. pacifica was found to be the most sensitive to Ni in acute exposure tests. In order to assess sublethal effects of Ni on copepod reproduction, the test organisms were exposed to four nominal Ni concentrations 0, 10, 100, 1000 microg l(-1) Ni. The results indicated that offspring production of T. japonicus and A. borneoensis was significantly reduced after exposure to 10 microg l(-1) Ni. Whereas egg production and egg hatching success of A. pacifica were significantly reduced at 100 and 10 microg l(-1) Ni, respectively. Exposure of copepods to the highest Ni concentration caused a severely reduced nauplii production from T. japonicus, A. borneoensis and A. pacifica by 87.8, 56.9 and 65.8%, respectively, and a significantly reduced egg production of A. pacifica by 74.4%. These results show that Ni excess in the coastal environment can have detrimental effects on reproduction of copepods.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10646-010-0471-6DOI Listing
June 2010
-->